These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
689 related items for PubMed ID: 16931170
21. Effect of concurrent elemental diet on infliximab treatment for Crohn's disease. Tanaka T, Takahama K, Kimura T, Mizuno T, Nagasaka M, Iwata K, Nakano H, Muramatsu M, Takazoe M. J Gastroenterol Hepatol; 2006 Jul; 21(7):1143-9. PubMed ID: 16824066 [Abstract] [Full Text] [Related]
22. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Sandborn WJ, Hanauer SB. Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177 [Abstract] [Full Text] [Related]
23. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088 [Abstract] [Full Text] [Related]
24. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, Peter HJ. Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632 [Abstract] [Full Text] [Related]
25. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study]. Doubremelle M, Bourreille A, Zerbib F, Heresbach D, Metman EH, Beau P, Gournay J, Galmiche JP. Gastroenterol Clin Biol; 2002 Nov; 26(11):973-9. PubMed ID: 12483127 [Abstract] [Full Text] [Related]
26. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease. Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS. J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339 [Abstract] [Full Text] [Related]
27. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS. Aliment Pharmacol Ther; 2008 Jul; 28(2):221-7. PubMed ID: 18485127 [Abstract] [Full Text] [Related]
28. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Atzeni F, Ardizzone S, Sarzi-Puttini P, Colombo E, Maconi G, De Portu S, Carrabba M, Bianchi Porro G. Aliment Pharmacol Ther; 2005 Sep 01; 22(5):453-61. PubMed ID: 16128684 [Abstract] [Full Text] [Related]
29. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G, Belgian Inflammatory Bowel Disease Research Group, North-Holland Gut Club. Gastroenterology; 2010 Feb 01; 138(2):463-8; quiz e10-1. PubMed ID: 19818785 [Abstract] [Full Text] [Related]
30. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Am J Gastroenterol; 2001 Mar 01; 96(3):722-9. PubMed ID: 11280541 [Abstract] [Full Text] [Related]
31. Clinical outcome of Crohn's disease treated with infliximab. Arslan S, Kav T, Besisik F, Kaymakoglu S, Pinarbasi B, Tözün N, Hamzaoglu HO, Duman D, Ulker A, Parlak E, Palabiyikoglu M, Dökmeci A. Hepatogastroenterology; 2003 Mar 01; 50(52):952-6. PubMed ID: 12845957 [Abstract] [Full Text] [Related]
32. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen. Domènech E, Zabana Y, Mañosa M, Garcia-Planella E, Cabré E, Gassull MA. J Clin Gastroenterol; 2010 Jan 01; 44(1):34-7. PubMed ID: 19417683 [Abstract] [Full Text] [Related]
33. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G, Claessens C, Humblet E, Vande Casteele N, Gils A, Rutgeerts P. Gut; 2012 Feb 01; 61(2):229-34. PubMed ID: 21948942 [Abstract] [Full Text] [Related]
34. Infliximab use in luminal Crohn's disease. Richter JA, Bickston SJ. Gastroenterol Clin North Am; 2006 Dec 01; 35(4):775-93. PubMed ID: 17129813 [Abstract] [Full Text] [Related]
36. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L. Ann Rheum Dis; 2005 May 01; 64(5):704-7. PubMed ID: 15485995 [Abstract] [Full Text] [Related]
38. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S. Gastroenterology; 2015 Jun 01; 148(7):1320-9.e3. PubMed ID: 25724455 [Abstract] [Full Text] [Related]
39. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania. Gheorghe L, Gheorghe C, Badea M, Vădan R, Pârvulescu I, Toader C, Tugui L, Papuc O, Ionescu R, Preda C, Călin I, Diculescu M. Rom J Gastroenterol; 2003 Mar 01; 12(1):7-13. PubMed ID: 12673373 [Abstract] [Full Text] [Related]
40. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, Spencer MP. Dis Colon Rectum; 2007 Nov 01; 50(11):1754-60. PubMed ID: 17899271 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]